SCHEMBL5539792

SCHEMBL5539792

[CH2]C(=O)N1CCN(Cc2c(C)cc(C)cc2C)CC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.48
GALR3 O60755 2/20 0.41
NR2F2 P24468 2/20 0.41
ALDH1A1 P00352 3/20 0.40
GRIN2B Q13224 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
HTT P42858 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALOX15 P16050 1/20 0.39
GPR183 P32249 1/20 0.39
MAPT P10636 1/20 0.38
ATM Q13315 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539795 0.85 HRH3 (0.53) EPHX2GALR3NR2F2ALDH1A1GRIN2B
SCHEMBL5537915 0.80 GRIN2B (0.62) ALDH1A1GRIN2BMEN1KMT2AMAPT
SCHEMBL9987629 0.79 ALDH1A1 (0.48) EPHX2GALR3NR2F2ALDH1A1KDM4E
SCHEMBL11891933 0.75 HRH3 (0.52) EPHX2ALDH1A1KDM4EHRH3ALOX15
SCHEMBL5537445 0.75 ATM (0.64) ALDH1A1KDM4EHRH3MEN1KMT2A
SCHEMBL10701848 0.74 HRH3 (0.46) EPHX2ALDH1A1HRH3MEN1KMT2A
SCHEMBL10702796 0.73 EPHX2 (0.44) EPHX2ALDH1A1HRH3HTTMAPT
SCHEMBL5542065 0.73 EPHX2 (0.44) EPHX2ALDH1A1HRH3MEN1KMT2A
SCHEMBL26121408 0.72 HRH3 (0.47) EPHX2HRH3MEN1KMT2A
SCHEMBL593755 0.70 LMNA (0.50) EPHX2ALDH1A1HRH3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 EPHX2 3662/4885GALR3 1606/4885NR2F2 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.